Jose Manuel Otero, the Chief Operating Officer of $LXEO, sold 3,016 shares of the company on 02-18-2026 for an estimated $19,293. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.3% of their shares of this class of stock. Following this trade, they now own 125,460 shares of this class of $LXEO stock.
$LXEO Insider Trading Activity
$LXEO insiders have traded $LXEO stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $LXEO stock by insiders over the last 6 months:
- RICHARD NOLAN TOWNSEND (Chief Executive Officer) has made 0 purchases and 4 sales selling 24,433 shares for an estimated $192,807.
- TAI SANDI SEE (Chief Development Officer) has made 0 purchases and 3 sales selling 4,274 shares for an estimated $38,345.
- JOSE MANUEL OTERO (Chief Operating Officer) has made 0 purchases and 3 sales selling 5,131 shares for an estimated $38,206.
- JENNY ROBERTSON (Chief Legal Officer) has made 0 purchases and 3 sales selling 4,075 shares for an estimated $36,619.
- ERIC ADLER (Chief Medical Officer) has made 0 purchases and 3 sales selling 3,997 shares for an estimated $35,943.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LXEO Hedge Fund Activity
We have seen 106 institutional investors add shares of $LXEO stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 5,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $49,650,000
- PARADIGM BIOCAPITAL ADVISORS LP added 4,763,198 shares (+inf%) to their portfolio in Q4 2025, for an estimated $47,298,556
- AVORO CAPITAL ADVISORS LLC added 3,300,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $32,769,000
- BLACKROCK, INC. added 2,736,471 shares (+126.0%) to their portfolio in Q4 2025, for an estimated $27,173,157
- STATE STREET CORP added 2,642,877 shares (+485.1%) to their portfolio in Q4 2025, for an estimated $26,243,768
- BALYASNY ASSET MANAGEMENT L.P. removed 2,278,762 shares (-58.2%) from their portfolio in Q4 2025, for an estimated $22,628,106
- ORBIMED ADVISORS LLC added 2,125,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $21,101,250
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LXEO Analyst Ratings
Wall Street analysts have issued reports on $LXEO in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/13/2026
- Raymond James issued a "Strong Buy" rating on 12/18/2025
- Cantor Fitzgerald issued a "Overweight" rating on 12/01/2025
- Chardan Capital issued a "Buy" rating on 11/05/2025
- Leerink Partners issued a "Outperform" rating on 10/07/2025
To track analyst ratings and price targets for $LXEO, check out Quiver Quantitative's $LXEO forecast page.
$LXEO Price Targets
Multiple analysts have issued price targets for $LXEO recently. We have seen 6 analysts offer price targets for $LXEO in the last 6 months, with a median target of $19.5.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $17.0 on 01/13/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $10.0 on 01/13/2026
- Christopher Raymond from Raymond James set a target price of $25.0 on 12/18/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $19.0 on 12/01/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $30.0 on 10/15/2025
- Mani Foroohar from Leerink Partners set a target price of $20.0 on 10/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
